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Introduction
Demographic data clearly demonstrate that the percen-
tage of the population in the older age group is
increasing. Androgen deﬁciency in the aging male has
become a topic of increasing interest and debate
throughout the world. Cross-sectional and longitudinal
data indicate that the testosterone falls progressively
with age and that a signiﬁcant percentage of men
over the age of 60 years have serum testosterone
levels that are below the lower limits of youngadult (age
20–30 years) men (1–4). The principal questions raised
by these observations are whether older hypogonadal
men will beneﬁt from testosterone treatment and what
will be the risks associated with such intervention.
The past decade has brought evidence of beneﬁt of
androgen treatment of hypogonadal men on multiple
target organs and the recent studies show short-term
beneﬁcial effects of testosterone in older men that are
similar to those in younger men. This has been
comprehensively reviewed and summarized by the
Institute of Medicine in ‘Testosterone and Aging: Clinical
Research Directions’ (5). Long-term data on the effects of
testosterone treatment in the older population are limited
mainly to effects on body composition and bone mass
(6–11). Key questions of the effects of testosterone on
patientreportedoutcomesandfunctionalbeneﬁtsthatmay
retard physical or mental frailty of the elderly or improve
the qualityof life are not yet available. Speciﬁc risk data on
the prostate and cardiovascular systems are needed.
Process for development of
recommendations
Recentguidelinesforthetestosteronetreatmentofyounger
hypogonadal men are available from professional societies
(12–14). Recommendations on the diagnosis, treatment,
and monitoring of late-onset hypogonadism (LOH) were
published by International Society for the Study of Aging
Male (ISSAM)in2002(15).In 2005, awritingcommittee
formedbytheInternationalSocietyofAndrology(ISA),the
ISSAM, and the European Association of Urology (EAU)
prepared a set of recommendations speciﬁcally on the
‘Investigation, treatment and monitoringof LOH’. In order
to reach a large audience, these recommendations were
published in the International Journal of Andrology, the
Journal of Andrology, the Aging Male, and European
Urology (16–19).I nv i e wo ft h eg r o w i n gi n t e r e s tf r o m
practitioners on the treatment of older men with
testosterone, the ISA, ISSAM, EAU, European Academy of
Andrology, and American Society of Andrology convened
meetings of the writing group with expert representatives
from each of the societies. The writing group membership
from 2005 was expanded to include additional urologists.
MembersofthewritinggroupmetinBerlin2007,Toronto
2007,andTampa 2008 to revise these recommendations.
There was no corporate funding or support for the
development of these recommendations. The revised
recommendations are supported by a selection of appro-
priate references and categorized by the level of evidence
and grade of recommendation according to the US
Department of Health and Human Services, Public Health
Service, Agency for Health Care Policy and Research
(1992; Table 1).
To ensure broad outreach to multidisciplinary
audiences, these recommendations are published in
several journals simultaneously.
Recommendation 1: deﬁnition
LOH, also referred to as age-associated testosterone-
deﬁciency syndrome (TDS), is a clinical and biochemical
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t e r i z e db ys y m p t o m sa n dad e ﬁ c i e n c yi ns e r u m
testosterone levels (below the young healthy adult
male reference range) (16–20). This condition may
result in signiﬁcant detriment in the quality of life and
adversely affect the function of multiple organ systems.
Recommendation 2: clinical diagnosis
and questionnaires
2.1. At present, the diagnosis of treatable hypogonad-
ism requires the presence of symptoms and signs
suggestive of testosterone deﬁciency (Level 3, Grade A)
(12, 16–19). The symptom most associated with
hypogonadism is low libido (Level 3, Grade A) (21,
22). Other manifestations of hypogonadism include:
erectile dysfunction, decreased muscle mass and
strength, increased body fat, decreased bone mineral
density and osteoporosis, and decreased vitality and
depressed mood. None of these symptoms are speciﬁc to
the low androgen state but may raise suspicion of
testosterone deﬁciency. One or more of these symptoms
must be corroborated with a low serum testosterone
level (Level 3, Grade A) (1, 23–25).
2.2. Questionnaires such as Aging Male Symptom
Score (AMS) (26, 27) and Androgen Deﬁciency in
Aging Men (ADAM) (28) are not recommended for the
diagnosis of hypogonadism because of low speciﬁcity
(Level 3, Grade B) (24, 29, 30).
Recommendation 3: laboratory diagnosis
3.1. In patients at risk or suspected of hypogonadism, a
thorough physical and biochemical work-up is necess-
ary (Level 4, Grade A). Transient decreases of serum
testosterone levels such as those due to acute illnesses
should be excluded by careful clinical evaluations and
repeated hormone measurement. Hypogonadism
(primary or secondary) can occur at all ages including
elderly men. Risk factors for hypogonadism in older men
may include chronic illnesses (including diabetes
mellitus, chronic obstructive lung disease, inﬂam-
matory arthritic disease, renal disease, and HIV-related
disease), obesity, metabolic syndrome, and hemochro-
matosis (12). Such chronic diseases should be investi-
gated and treated (Level 4, Grade A).
3.2. A serum sample for total testosterone determina-
tion should be obtained between 0700 and 1100 h
(Level 2a, A) (31). The most widelyaccepted parameters
to establish the presence of hypogonadism is the
measurement of serum total testosterone. There are
no generally accepted lower limits of normal. There is,
however, general agreement that the total testosterone
level above 12 nmol/l (350 ng/dl) does not require
substitution. Similarly, based on the data of younger
men, there is consensus that patients with serum total
testosterone levels below 8 nmol/l (230 ng/dl) will
usually beneﬁt from testosterone treatment. If the
serum total testosterone level is between 8 and
12 nmol/l, repeating the measurement of total tes-
tosterone with sex hormone-binding globulin (SHBG) to
c a l c u l a t ef r e et e s t o s t e r o n eo rf r e et e s t o s t e r o n eb y
equilibrium dialysis may be helpful (see 3.5 and 3.7
below) (Level 2b, Grade A).
3.3. Measurements of serum luteinizing hormone will
assist in differentiating between primary and secondary
hypogonadismandserumprolactinisindicatedwhenthe
serum testosterone is lower than 5.2 nmol/l (150 ng/dl)
(32–35) or when secondary hypogonadism is suspected
(12, 36, 37) (Level 3, Grade B).
3.4. Since there are known variations between assay
methods, it is imperative that the practitioners utilize
reliable laboratories and are acquainted with the
reference ranges for testosterone from their local
laboratory (38–41) (Level 2b, Grade A).
3.5. Current immunometric methods for the
measurement of testosterone can distinguish between
hypogonadism and normal adult men. However, the
methods based on mass spectrometryare more accurate
and precise (39–41) (Level 2b, Grade A) and are
increasingly recognized as the method of choice for
serum testosterone measurement.
Table 1 Level of evidence and grade of recommendation utilized in the recommendations.
Level Type of evidence
1a Evidence obtained from meta-analysis of randomized trials
1b Evidence obtained from at least one randomized trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies, and
case reports
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities
Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the speciﬁc recommendations and including at least
one randomized trial
B Based on well-conducted clinical studies, but without randomized clinical trials
C Made despite the absence of directly applicable clinical studies of good quality
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one should be considered when the serum total
testosterone concentration is not diagnostic of hypogo-
nadism, particularly in obese men. There are no
generally accepted lower limits of normal for free
testosterone for the diagnosis of hypogonadism.
However, a free testosterone level below 225 pmol/l
(65 pg/ml)canprovidesupportiveevidencefor testoster-
one treatment(37,38,42)(Level3,Grade C).Threshold
values for bioavailable testosterone depend on the
method used and are not generally available (38).
3.7. Equilibrium dialysis is the gold standard for free
testosterone measurement. Free testosterone assays
based on analog displacement immunoassays are
widely available but do not give an accurate measure-
ment of free testosterone; thus they should not be used
(43, 44). Alternately, measuring serum SHBG levels
together with reliable serum total testosterone levels
provides the data necessary for calculating free
testosterone levels (Level 2b, Grade A). Calculated free
testosterone correlates well with free testosterone by
equilibrium dialysis (38, 42).
Effortstocreatestandardizationoftestosteroneassays,
agreement on standards for testosterone measurement
and accurate reference ranges for testosterone by liquid
chromatography mass spectrometry (LC–MS)/MS are
being developed. International reference standards,
characterization of methodology, and population-based
reference ranges for free testosterone by equilibrium
dialysis are needed. Consensus on the equilibrium
constants for testosterone binding to SHBG and albumin
will allow improved calculation offree testosterone (38).
3.8. Salivary testosterone has also been shown to be a
reliable substitute for free testosterone measurements
but cannot be recommended for general use at this time,
since the methodology has not been standardized and
adult male ranges are not available in most hospital or
reference laboratories (45) (Level 3, Grade B).
3.9. Alterations in other endocrine systems occur in
association with aging (i.e., estradiol, growth hormone
(GH), and DHEA) but the signiﬁcance of these changesis
not well understood. Determinations of estradiol,
thyroid hormones, cortisol, DHEA, DHEA-S, melatonin,
GH, and insulin-like growth factor-I are not indicated
unless other endocrine disorders are suspected based on
the clinical signs and symptoms of the patient (12)
(Level 2, Grade A).
Recommendation 4: assessment of
treatment outcome and decisions on
continued therapy
Improvement in signs and symptoms of testosterone
deﬁciency should be sought. Failure to beneﬁt clinical
manifestations within a reasonable time interval (3–6
months is adequate for libido and sexual function,
muscle function, and improved body fat; improvement
in bone mineral density requires a longer interval
to show improvement) should result in discontinuation
of treatment. Further investigation for other causes of
symptoms is then mandatory (Level 1b, Grade A).
Recommendation 5: body composition
In men with hypogonadal values of testosterone,
testosterone administration improves body composition
(decrease of fat mass, increase of lean body mass (5, 7,
9, 10, 46) (Level 1b, Grade A). Secondary beneﬁts of
these changes of body composition on strength, muscle
function, and metabolic and cardiovascular dysfunction
are suggested byavailable databut require conﬁrmation
by large-scale studies.
Recommendation 6: bone density and
fracture rate
Osteopenia, osteoporosis, and fracture prevalence rates
are greater in hypogonadal younger and older men (47).
Bone density in hypogonadal men of all ages increases
under testosterone substitution (8, 11, 48) (Level 1b,
GradeA).Fracturedataarenotyetavailableandthusthe
long-term beneﬁt of testosterone requires further investi-
gation. Assessment of bone density at 2-year intervals is
advisable in hypogonadal men and serum testosterone
measurements should be obtained in all men with
osteopenia (49, 50).
Recommendation 7: testosterone and
sexual function
7.1. The initial assessment of all men with erectile
dysfunction and/or diminished libido should include
determination of serum testosterone. These dysfunc-
tions, with or without a testosterone deﬁciency, might
be related to co-morbidities (i.e., diabetes mellitus,
hyperprolactinemia, the metabolic syndrome, bladder
outlet obstruction, peripheral vascular disease, or
medications (51)) (Level 2a, Grade A).
7.2. Men with erectile dysfunction and/or diminished
libido and documented testosterone deﬁciency are
candidates for testosterone therapy (Level 2a, Grade
A). An inadequate response to testosterone treatment
requires reassessment of the causal mechanisms
responsible for the erectile dysfunction (see 7.4 below).
7.3. In the presence of a clinical picture of testoster-
one deﬁciency and borderline serum testosterone levels,
a short (e.g., 3 months) therapeutic trial may be
justiﬁed. An absence of response calls for discontinu-
ation of testosterone administration. A satisfactory
response might be placebo generated, so that continued
assessment is advisable before long-term treatment is
recommended (52) (Level 2a, Grade B).
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gism with combined use of testosterone and phospho-
diesterase-5 inhibitors in hypogonadal or borderline
eugonadal men (53, 54) (Level 1b, Grade B). These
observations are still preliminary and require additional
study. However, the combination treatment should be
considered in hypogonadal patients with erectile
dysfunction failing to respond to either treatment
alone. It is unclear whether men with hypogonadism
and erectile dysfunction should be treated initially with
phosphodiesterase-5 inhibitor (PDE-5-I), testosterone,
or the combination of the two.
Recommendation 8: testosterone and
obesity, metabolic syndrome and type
2 diabetes
8.1. Many of the components of the metabolic syn-
drome (obesity, hypertension, dyslipidemia, impaired
glucose regulation, and insulin resistance) are also
present in hypogonadal men. Numerous epidemiologi-
cal studies have established a close relationship between
obesity and low serum testosterone levels in healthy
men (55). Obese men of 20–64% have a low serum total
or free testosterone levels (56). The metabolic syndrome
and type 2 diabetes mellitus are associated with low
plasma testosterone (25, 55, 57–62). Serum testoster-
one should be measured in men with type 2 diabetes
mellitus with symptoms suggestive of testosterone
deﬁciency (Level 2b, Grade A).
8.2. The effects of testosterone administration on
glycemic control of men with diabetes mellitus are much
less certain (63–65). It is premature to recommend
testosterone treatment for the metabolic syndrome or
diabetes mellitus in the absence of laboratory and other
clinical evidence of hypogonadism. In men with hypogo-
nadism and diabetes and/or the metabolic syndrome, the
testosteronetreatmentfor traditionalhypogonadalsymp-
tomsmayhaveotherunprovenbeneﬁtsontheirmetabolic
status (Level 2a, Grade B).
Recommendation 9: prostate cancer
and benign prostatic hyperplasia (BPH)
9.1. At the present time, there is no conclusive evidence
that testosterone therapy increases the risk of prostate
cancer or BPH (66, 67). There is also no evidence that
testosterone treatment will convert subclinical prostate
cancer to clinically detectable prostate cancer (Level 4,
Grade C). However, there is unequivocal evidence that
testosterone can stimulate growth and aggravate
symptoms in men with locally advanced and metastatic
prostate cancer (68, 69) (Level 2a, Grade A). Currently,
adequately powered and optimally designed long-term
prostate disease data are not available to determine
whether there is any additional risk from testosterone
replacement. Hypogonadal older (O45 years) men
should be counseled on the potential risks and beneﬁts
of testosterone replacement before treatment and care-
fully monitored for prostate safety during treatment
(Level 3, Grade A).
9.2. Prior to therapy with testosterone, a man’s risk
of prostate cancer must be assessed using, as a
minimum, digital rectal examination (DRE) and
determination of serum prostate-speciﬁc antigen
(PSA). However, the pretreatment assessment can be
improved by incorporating other risk predictors such as
age, family history, and ethnicity/race. Several tools
have been developed to assist the clinician in assessing
prostate cancer risk (e.g., on-line prostate cancer risk
calculator) (70, 71). These tools have not beenvalidated
for patients with LOH TDS. If the patient and physician
feel that the risk is sufﬁciently high, further assessment
may be desirable (71, 72) (Level 2a, Grade B). However,
pretreatment prostate ultrasound examinations or
biopsies are not recommended as routine requirements.
9.3. After initiation of testosterone treatment,
patients should be monitored for prostate disease at
3–6 months, 12 months, and at least annually
thereafter (Level 3, Grade C). Should the patient’s
prostate cancer risk be sufﬁciently high (suspicious
ﬁnding on DRE; increased PSA or as calculated using a
combination of risk factors as noted above) transrectal
ultrasound-guided biopsies of the prostate are indicated
(73–76) (Level 2b, Grade A).
9.4. Severe symptoms of lower urinary tract symp-
toms (LUTS) evident by a high (O21) International
Prostate Symptom Score due to benign prostate
hyperplasia represents a relative contraindication
(although there are no compelling data to suggest
that testosterone treatment causes exacerbation of
LUTS or promotes acute urinary retention) (Level 3,
Grade C). After successful treatment of lower urinary
tract obstruction, this contraindication is no longer
applicable (Level 4, Grade C).
9.5. Men successfully treated for prostate cancer and
suffering from conﬁrmed symptomatic hypogonadism
are potential candidates for testosterone substitution
after a prudent interval, if there is no clinical or
laboratory evidence of residual cancer (77–80).A s
long-term outcome data are not available, clinicians
must exercise good clinical judgment together with
adequate knowledge of advantages and drawbacks of
testosterone therapy in this situation (81, 82) (Level 2b,
Grade C). The risk and beneﬁts must be clearlydiscussed
with and understood by the patient and the follow-up
must be particularly careful.
Recommendation 10: treatment and
delivery systems
10.1. Preparationsofnaturaltestosteroneshouldbeused
for substitution therapy. Currently available i.m.,
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testosteronearesafeandeffective(Level1b,GradeA).The
treating physician should have sufﬁcient knowledge and
adequate understanding of the pharmacokinetics as well
as of the advantages and drawbacks of each preparation.
The selectionofthe preparationshouldbeajointdecision
of an informed patient and physician (83).
10.2. Since the possible development of an adverse
event during treatment (especially elevated hematocrit
or prostate carcinoma) (84) requires rapid discontinu-
ation of testosterone substitution, short-acting prep-
arations may be preferred over long-acting depot
preparations in the initial treatment of patients with
LOH (Level 4, Grade C).
10.3. Inadequate data are available to determine the
optimal serum testosterone level for efﬁcacy and safety.
For the present time, mid to lower young adult male
serum testosterone levels seem appropriate as the
therapeutic goal (85). Sustained supraphysiological
levels should be avoided. No evidence exists for or
against the need to maintain the physiological circadian
rhythm of serum testosterone levels (Level 3, Grade B).
10.4. Obese men are more likely to develop adverse
effects (83, 85) (Level 2b, Grade B).
10.5. 17-a-alkylated androgen preparations such as
17a-methyl testosterone are obsolete because of their
potential liver toxicity and should no longer be
prescribed (Level 2b, Grade A).
10.6. There is not enough evidence to recommend
substitution of DHT in aging men; other non-testoster-
one androgen precursor preparations such as DHEA,
DHEA-S, androstenediol, or androstenedione are not
recommended (Level 1b, Grade A).
10.7. Humanchorionicgonadotropin(hCG)stimulates
testosterone production of Leydig cells, albeit at a lower
rate in older than in younger men. Since insufﬁcient
information exists about the therapeutic and adverse
effects of hCG treatment in older men and its higher cost,
this treatment cannot be recommended in LOH except
when fertility is an issue (Level 1b, Grade B).
10.8. Anti-estrogens and aromatase inhibitors have
been shown to increase endogenous testosterone levels
(Level 2b, Grade B). Adequate evidence does not exist
to recommend their use. Selective androgen receptor
modulators are under development, but not yet
clinically available. Many of these compounds are non-
aromatizable and the risks of long-term use are unclear.
Recommendation 11: adverse effects and
monitoring
11.1. Testosterone treatment is contraindicated in men
with prostate or breast cancer (Level 3, Grade A).
Testosterone treatment is relatively contraindicated
in men at the high risk of developing prostate cancer.
It is unclear whether localized low-grade (Gleason score
!7) prostate cancer represents a relative or absolute
contraindication for treatment. (See Section 9 for more
details; Level 4, Grade, C) (83, 86, 87).
11.2. Men with signiﬁcant erythrocytosis (hemato-
crit O52%; Level 3, Grade A), untreated obstructive
sleep apnea (Level 3, Grade B), untreated severe
congestive heart failure (Level 3, Grade B) should not
be started on treatment with testosterone without prior
resolution of the co-morbid condition (83, 88).
11.3. Erythrocytosis can develop during testosterone
treatment, especially in older men treated by injectable
testosterone preparations. Periodic hematological
assessment is indicated, i.e., before treatment, then
3–4 and 12 months in the ﬁrst year of treatment
and annually thereafter. While it is not yet clear what
critical threshold is desirable, dose adjustments and/or
periodic phlebotomy may be necessary to keep hema-
tocrit below 52–55% (12, 82, 83) (Level 3, Grade A).
Recommendation 12: summary
Age is not a contraindication to initiate testosterone
treatment. Individual assessment of co-morbidities (as
possible causes of symptoms) and potential risks versus
beneﬁts of testosterone treatment is particularly import-
ant in elderly men (Level 2a, Grade A).
Conclusion
The diagnosis of late-onset testosterone deﬁciency is
based on the presence of symptoms or signs and
persistent low serum testosterone levels. The beneﬁts
and risks of testosterone therapy must be clearly
discussed with the patient and assessment of prostate
and other risk factors considered before commencing
testosterone treatment. Response to testosterone treat-
ment should be assessed. If there is no improvement of
symptoms and signs, treatment should be withdrawn
and the patient investigated for other possible causes of
the clinical presentations.
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